These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29520905)

  • 21. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
    Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.
    Asselah T
    J Hepatol; 2014 Aug; 61(2):435-8. PubMed ID: 24816173
    [No Abstract]   [Full Text] [Related]  

  • 25. The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.
    Guedj J; Dahari H; Uprichard SL; Perelson AS
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):397-9. PubMed ID: 23899277
    [No Abstract]   [Full Text] [Related]  

  • 26. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
    Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
    Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies].
    Lu J; Zhou HJ; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):147-150. PubMed ID: 29804384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Weng Q; Li X; Ren H; Xie J; Pan X; Xu J; Chen N
    Oncotarget; 2017 Mar; 8(13):22299-22303. PubMed ID: 28223549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
    Kai Y; Hikita H; Tatsumi T; Nakabori T; Saito Y; Morishita N; Tanaka S; Nawa T; Oze T; Sakamori R; Yakushijin T; Hiramatsu N; Suemizu H; Takehara T
    J Gastroenterol; 2015 Nov; 50(11):1145-51. PubMed ID: 26208695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daclatasvir plus sofosbuvir for HCV infection.
    Dhaliwal HS; Nampoothiri RV
    N Engl J Med; 2014 Apr; 370(16):1560. PubMed ID: 24738675
    [No Abstract]   [Full Text] [Related]  

  • 33. Daclatasvir plus sofosbuvir for HCV infection.
    Sulkowski MS; Jacobson IM; Nelson DR
    N Engl J Med; 2014 Apr; 370(16):1560-1. PubMed ID: 24738674
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
    Hussain N; Farooq N; Maqsood M; Rajoka MSR; Bilal M
    Arch Microbiol; 2021 Jul; 203(5):2365-2371. PubMed ID: 33660021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
    Pérez-Pitarch A; Guglieri-López B; Ferriols-Lisart R; Merino-Sanjuán M
    Int J Antimicrob Agents; 2016 Mar; 47(3):184-94. PubMed ID: 26915476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
    Brochot E; Bodeau S; Duverlie G
    Ther Drug Monit; 2015 Aug; 37(4):550-1. PubMed ID: 25525764
    [No Abstract]   [Full Text] [Related]  

  • 39. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 40.  Effect of ezetimibe in HCV viral load after liver transplantation.
    Monrroy-Bravo H; Angulo J; Pino K; Labbé P; López-Lastra M; Soza A
    Ann Hepatol; 2016; 15(5):803-5. PubMed ID: 27493122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.